Biophytis S.A. Total Liabilities

Latest as of June 2025: €14.44 Million EUR ≈ $16.88 Million USD

Biophytis S.A. total liabilities. Based on the latest financial reports, Biophytis S.A. (ALBPS) has total liabilities worth €14.44 Million EUR (≈ $16.88 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ALBPS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Biophytis S.A. (2012–2024)

Total liabilities of Biophytis S.A. from 2012 to 2024. This chart illustrates how Biophytis S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore how much of Biophytis S.A.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.

Biophytis S.A. Competitors by Total Liabilities

The table below lists competitors of Biophytis S.A. ranked by their total liabilities.

Company Country Total Liabilities
Baker Steel Resources Trust
LSE:BSRT
UK GBX184.80K
CBEYOND
F:C5B
Germany €400.03K
Central China Real Estate Limited
F:AJ5
Germany €103.47 Billion
Im Cannabis Corp
NASDAQ:IMCC
USA $35.35 Million
Avinger Inc
NASDAQ:AVGR
USA $9.73 Million
BELGRAVIA HARTFORD CAP.
F:ECA
Germany €2.63 Million
Next Biometrics Group ASA
OL:NEXT
Norway Nkr28.44 Million
Pharos Energy plc
LSE:PHAR
UK GBX127.90 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Biophytis S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Biophytis S.A. asset portfolio.

Liquidity & Leverage Metrics

Biophytis S.A. Total Liabilities Ratios Explained

Biophytis S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.35 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.08 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.86 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 2.18 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Biophytis S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Biophytis S.A. (2012–2024)

The table below shows the annual total liabilities of Biophytis S.A. from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 €16.60 Million
≈ $19.41 Million
+4.76%
2023-12-31 €15.85 Million
≈ $18.53 Million
-33.68%
2022-12-31 €23.90 Million
≈ $27.94 Million
-21.79%
2021-12-31 €30.56 Million
≈ $35.72 Million
+49.95%
2020-12-31 €20.38 Million
≈ $23.82 Million
-19.13%
2019-12-31 €25.20 Million
≈ $29.46 Million
+69.61%
2018-12-31 €14.86 Million
≈ $17.37 Million
+212.04%
2017-12-31 €4.76 Million
≈ $5.57 Million
+22.90%
2016-12-31 €3.87 Million
≈ $4.53 Million
+109.34%
2015-12-31 €1.85 Million
≈ $2.16 Million
+22.09%
2014-12-31 €1.52 Million
≈ $1.77 Million
+46.15%
2013-12-31 €1.04 Million
≈ $1.21 Million
-4.36%
2012-12-31 €1.08 Million
≈ $1.27 Million
--

About Biophytis S.A.

PA:ALBPS France Biotechnology
Market Cap
$1.52 Million
€1.30 Million EUR
Market Cap Rank
#30328 Global
#559 in France
Share Price
€0.03
Change (1 day)
-7.78%
52-Week Range
€0.01 - €0.13
All Time High
€4896.00
About

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more